52605-97-7

Basic information

• Product Name: 2,3-Dimethoxypyridine
• Synonyms: 2,3-DIMETHOXYPYRIDINE;PYRIDINE, 2,3-DIMETHOXY-;2,3-Dimethoxypyridine ,98%
• CAS NO: 52605-97-7
• Molecular Formula: C₇H₉NO₂
• Molecular Weight: 139.15
• Product Categories: Pyridine;Pyridine series;Pyridines derivates;Pyridines;Aromatics Compounds;Aromatics;Bases & Related Reagents;Nucleotides;Boronic Acid
• Mol File: 52605-97-7.mol
• Article Data: 10

Chemical Properties

• Boiling Point: 98-100°C 16mm
• Flash Point: 98-100°C/16mm
• Appearance: Yellow Liquid
• Density: 1,104 g/cm3
• Vapor Pressure: 1.25mmHg at 25°C
• Refractive Index: 1.5205
• Storage Temp.: Refrigerator
• Solubility: Chloroform, Ethyl Acetate
• PKA: 4.70±0.10(Predicted)
• BRN: 1526067
• CAS DataBase Reference: 2,3-Dimethoxypyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 2,3-Dimethoxypyridine(52605-97-7)
• EPA Substance Registry System: 2,3-Dimethoxypyridine(52605-97-7)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-37-36/37
• HazardClass: IRRITANT
• Hazardous Substances Data: 52605-97-7(Hazardous Substances Data)

Usage

Chemical Properties

Yellow Liquid

Uses

2,3-Dimethoxypyridine (cas# 52605-97-7) is a compound useful in organic synthesis.

InChI:InChI=1/C7H9NO2/c1-9-6-4-3-5-8-7(6)10-2/h3-5H,1-2H3

Upstream product

• 2402-77-9 2,3-dichloro-pyridine 
• 124-41-4 sodium methylate 
• 52605-96-6 2-chloro-3-methoxypyridine 
• 67-56-1 methanol 
• 109-09-1 2-chloropyridine 
• 6636-78-8 2-chloro-3-hydroxypyridine 
• 24100-18-3 2-bromo-3-methoxypyridine 

Downstream Products

• 1083168-92-6 2,3-dimethoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine 
• 76470-34-3 5,6-dimethoxynicotinic acid 
• 1590408-75-5 C₁₈H₁₃F₃N₄O₃ 
• 1590410-70-0 C₁₄H₈BrF₃N₂O₃ 
• 944906-83-6 C₈H₉NO₄ 
• 1112851-31-6 5,6-dimethoxypyridine-3-carbonitrile 
• 1581767-45-4 C₁₃H₁₁BrFNO₂ 
• 1581767-44-3 C₁₃H₁₁BrFNO₂ 
• 1581767-05-6 6-bromo-5-(3-fluorophenyl)-3-hydroxypyridin-2(1H)-one 
• 1581767-06-7 5-bromo-6-(3-fluorophenyl)-3-hydroxypyridin-2(1H)-one 
• 1469896-44-3 6-bromo-5-(4-fluorophenyl)-2,3-dimethoxypyridine 
• 1469896-46-5 5-bromo-6-(4-fluorophenyl)-2,3-dimethoxypyridine 
• 1581767-04-5 6-bromo-5-(4-fluorophenyl)-3-hydroxypyridin-2(1H)-one 
• 1581767-03-4 5-bromo-6-(4-fluorophenyl)-3-hydroxypyridin-2(1H)-one 

Relevant articles and documents

D-AMINO ACID OXIDASE INHIBITORS AND THERAPEUTIC USES THEREOF

The present invention relates to compounds of Formula (I): or a pharmaceutically acceptable salt thereof, wherein: each of A, B, C, D, and E, independently, is C, N, N—H, O, S, or absent is a single bond or a double bond; each of X, Y, and Z, independentl

FSH RECEPTOR ANTAGONISTS

The invention relates to FSH receptor antagonist according to general formula (I) or a pharmaceutically acceptable salt thereof and to a pharmaceutical composition containing the same. The compounds can be used for the treatment and prevention of endometriosis, for the treatment and prevention of pre-menopausal and peri-menopausal hormone-dependent breast cancer, for contraception, and for the treatment of uterine fibroids and other menstrual-related disorders

CAMPTOTHECIN-ANALOG WITH A NOVEL, “FLIPPED” LACTONE-STABLE, E-RING AND METHODS FOR MAKING AND USING SAME

The present invention discloses: (i) a novel, lactone-stable, “flipped” E-ring camptothecin, pharmaceutically-acceptable salts, and/or analogs thereof; (ii) methods of synthesis of said novel, lactone-stable, “flipped” E-ring camptothecin, pharmaceutically-acceptable salts, and/or analogs thereof; (iii) pharmaceutically-acceptable formulations comprising said novel, lactone-stable, “flipped” E-ring camptothecin, pharmaceutically-acceptable salts, and/or analogs thereof, and, optionally, one or more additional chemotherapeutic agents; (iv) methods of administration of said novel, lactone-stable, “flipped” E-ring camptothecin, pharmaceutically-acceptable salts, and/or analogs thereof, and, optionally, one or more additional chemotherapeutic agents, to subjects in need thereof; and (v) devices for the administration of said novel, lactone-stable, “flipped” E-ring camptothecin, pharmaceutically-acceptable salts, and/or analogs thereof, and, optionally, one or more chemotherapeutic agents, to subjects in need thereof.